Honokiol (Biphenyl Neolignan · Anxiolytic · Neuroprotective)

Compound	Honokiol
Chemical class	Polyphenol — Biphenyl Neolignan
CAS	35354-74-6
Primary source	Magnolia officinalis (houpu magnolia bark)
Key applications	Anxiolytic, neuroprotective, anti-inflammatory, antitumour
Claim strength	Moderate
Typical form	Magnolia bark extract standardised to honokiol + magnolol; honokiol 50% isolate
Buy from Herbuno	Magnolol 50% Powder (Magnolia Bark Extract) | Standardized Magnolia officinalis → Honokiol 50% Powder (Magnolia Bark Extract) | Standardized Magnolia officinalis →

Name origin: From Magnolia + -ol (hydroxyl group). Honokiol is a biphenyl neolignan — two phenylpropanoid units connected by a direct biaryl bond. It co-occurs in magnolia bark with its isomer magnolol (dihydroxybiphenyl with identical molecular formula but different allyl group positions). Traditional use: Magnolia bark (Hou Po in TCM) is one of the oldest recorded Chinese herbal medicines, used for over 2,000 years for digestive disorders, anxiety, depression, cough, and as a muscle relaxant. The bark of Magnolia officinalis is used in Kampo (Japanese traditional medicine) preparations including Hange-koboku-to for anxiety and nausea. Honokiol is identified alongside magnolol as the primary bioactive neolignans responsible for these activities. Research trajectory: Honokiol has an extensive preclinical evidence base covering anxiolytic (GABA-A modulation), neuroprotective, anti-inflammatory, antiangiogenic, and antitumour mechanisms. It is one of the more extensively studied natural neolignans. Commercial source: Honokiol is commercially available as a high-purity standardised extract (50% HPLC) from Magnolia officinalis bark. See sourcing options below.

---

Evidence for Honokiol Applications

Anxiolytic activity: Honokiol is a positive allosteric modulator of GABA-A receptors at benzodiazepine and non-benzodiazepine binding sites, producing anxiolytic effects in rodent models (elevated plus maze) at 0.2–5 mg/kg without sedation at lower doses. Human pilot studies with magnolia bark extract (honokiol + magnolol standardised) show reductions in stress and anxiety scores. Claim strength: Moderate.

Neuroprotective and cognitive: Honokiol crosses the blood-brain barrier readily (high lipophilicity). It activates SIRT3 (mitochondrial sirtuin), reduces amyloid-beta aggregation, and protects against neuroinflammation in Alzheimer’s and Parkinson’s disease animal models. Cognitive improvement studies in aged mice are consistent. Claim strength: Moderate.

Anti-inflammatory and antioxidant: Honokiol inhibits NF-κB, COX-2, and 5-LOX, providing dual cyclooxygenase-lipoxygenase pathway coverage. Nrf2 activation contributes to cellular antioxidant induction. Anti-inflammatory effects documented in arthritis, lung injury, and colitis animal models. Claim strength: Moderate.

---

Dosage & Formulator Specification

Human clinical data from magnolia bark extract (combined honokiol + magnolol) preparations: 200–400 mg/day total extract (delivering 50–100 mg honokiol + magnolol combined) for stress and anxiety applications. For isolated honokiol at Herbuno’s 50% purity, 50–100 mg/day honokiol equivalent is a working formulation range.

Honokiol has low aqueous solubility (logP ~3.9). Lipid-based delivery (soft gels, phytosomes) significantly improves bioavailability. Some commercial magnolia bark extracts use phospholipid complexation for enhanced oral absorption. Thermostable; compatible with encapsulation formats. Specify honokiol content (HPLC) separately from total magnolol + honokiol when formulating with the isolated compound.

Safety note: magnolia bark preparations including honokiol have been associated with rare cases of hepatotoxicity in the context of multi-herb products, though causality is not clearly established. Include standard advisory language for long-term use and recommend monitoring in individuals with pre-existing liver conditions. No hepatotoxicity has been documented from purified honokiol at supplement doses in clinical studies.

---

Frequently Asked Questions — Honokiol

What is the difference between honokiol and magnolol?
Honokiol and magnolol are positional isomers with identical molecular formulas (C18H18O2) and both are allyl-dihydroxybiphenyls. They differ in the position of the allyl groups on the two phenyl rings. Honokiol has the 5′-allyl group; magnolol has a 5-allyl group. Pharmacologically, honokiol is generally more potent for anxiolytic and neuroprotective activities; magnolol has stronger anti-inflammatory potency in some assays. Co-formulation at their natural ratio provides complementary coverage.

Is honokiol from magnolia bark safe during pregnancy?
Magnolia bark preparations are generally contraindicated in pregnancy. Honokiol and magnolol have demonstrated uterine stimulant activity in preclinical studies at higher doses, and traditional use patterns in Japanese Kampo specifically exclude magnolia bark preparations in pregnancy. This contraindication should be included in advisory language for magnolia bark/honokiol-containing products.

Can honokiol replace benzodiazepines for anxiety management?
Honokiol should not be positioned as a benzodiazepine substitute. Its GABA-A modulation is real and documented, but at a different site and with lower potency than pharmaceutical benzodiazepines. For mild situational anxiety and stress management in the supplement context, magnolia bark extract with honokiol has meaningful clinical evidence. For anxiety disorder management, pharmaceutical options remain the evidence-based standard.

Is there a preferred honokiol:magnolol ratio in magnolia bark extract?
Most commercial magnolia bark extracts (including Herbuno’s 50% Honokiol) are standardised to total honokiol content. The natural ratio in M. officinalis bark is approximately 1:1 honokiol:magnolol by weight, though extraction and processing can alter this. For Herbuno’s Honokiol 50% powder, confirm whether this is total honokiol or combined honokiol + magnolol standardisation via CoA, as this affects dose calculation.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery